Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Shares Outstanding (Weighted Average) (2016 - 2025)

Sonoma Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $1.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 13.87% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 13.87%, while the annual FY2025 figure was $1.2 million, 172.75% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.7 million at Sonoma Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $4.9 million in Q2 2023 and troughed at $2219.0 in Q3 2021.
  • A 5-year average of $1.3 million and a median of $1.1 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 99.88% in 2021 and later surged 159074.46% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $2507.0 in 2021, then surged by 123832.99% to $3.1 million in 2022, then tumbled by 82.43% to $546000.0 in 2023, then surged by 168.13% to $1.5 million in 2024, then rose by 13.87% to $1.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SNOA at $1.7 million in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.